Clinical pregnancy rate for frozen embryo transfer with HRT: a randomized controlled pilot study comparing 1 week versus 2 weeks of oestradiol priming.


Journal

Reproductive biology and endocrinology : RB&E
ISSN: 1477-7827
Titre abrégé: Reprod Biol Endocrinol
Pays: England
ID NLM: 101153627

Informations de publication

Date de publication:
07 Jul 2023
Historique:
received: 03 05 2023
accepted: 16 06 2023
medline: 10 7 2023
pubmed: 8 7 2023
entrez: 7 7 2023
Statut: epublish

Résumé

Does a frozen-embryo transfer in an artificially-prepared endometrium (FET-HRT) cycle yield similar clinical pregnancy rate with 7 days of oestrogen priming compared to 14 days? This is a single-centre, randomized, controlled, open-label pilot study. All FET-HRT cycles were performed in a tertiary centre between October 2018 and January 2021. Overall, 160 patients were randomized, with a 1:1 allocation, into two groups of 80 patients each: group A (7 days of E2 prior to P4 supplementation) and group B (14 days of E2 prior to P4 supplementation). Both groups received single blastocyst stage embryos on the 6th day of vaginal P4 administration. The primary outcome was the feasibility of such strategy assessed as clinical pregnancy rate, secondary outcomes were biochemical pregnancy rate, miscarriage rate, live birth rate and serum hormone levels on the day of FET. Chemical pregnancy was assessed by an hCG blood test 12 days after FET and clinical pregnancy was confirmed by transvaginal ultrasound at 7 weeks. The analysis included 160 patients who were randomly assigned to either group A or group B on the seventh day of their FET-HRT cycle if the measured endometrial thickness was above 6.5 mm. Following screening failures and of drop-outs, 144 patients were finally included both in group A (75 patients) or group B (69 patients). Demographic characteristics for both groups were comparable. The biochemical pregnancy rate was 42.5% and 48.8% for group A and group B, respectively (p 0.526). Regarding the clinical pregnancy rate at 7 weeks, no statistical difference was observed (36.3% vs 46.3% for group A and group B, respectively, p = 0.261). The secondary outcomes of the study (biochemical pregnancy, miscarriage, and live birth rate) were comparable between the two groups for IIT analysis, as well as the P4 values on the day of FET. In a frozen embryo transfer cycle, performed with artificial preparation of the endometrium, 7 versus 14 days of oestrogen priming are comparable, in terms of clinical pregnancy rate; the advantages of a seven-day protocol include the shorter time to pregnancy, reduced exposure to oestrogens, and more flexibility of scheduling and programming, and less probability to recruit a follicle and have a spontaneous LH surge. It is important to keep in mind that this study was designed as a pilot trial with a limited study population as such it was underpowered to determine the superiority of an intervention over another; larger-scale RCTs are warranted to confirm our preliminary results. Clinical trial number: NCT03930706.

Identifiants

pubmed: 37420186
doi: 10.1186/s12958-023-01111-8
pii: 10.1186/s12958-023-01111-8
pmc: PMC10326948
doi:

Substances chimiques

Estradiol 4TI98Z838E
Estrogens 0

Banques de données

ClinicalTrials.gov
['NCT03930706']

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

62

Informations de copyright

© 2023. The Author(s).

Références

N Engl J Med. 2018 Jan 11;378(2):126-136
pubmed: 29320646
N Engl J Med. 1986 Mar 27;314(13):806-11
pubmed: 3951513
Hum Reprod. 2019 Apr 1;34(4):679-688
pubmed: 30811549
Placenta. 2017 Dec;60:119-129
pubmed: 28693893
J Assist Reprod Genet. 2010 Jul;27(7):357-63
pubmed: 20373015
J Clin Endocrinol Metab. 1989 Apr;68(4):801-7
pubmed: 2921311
J Ovarian Res. 2022 Mar 21;15(1):36
pubmed: 35313944
Cochrane Database Syst Rev. 2016 Jun 30;(6):CD002118
pubmed: 27357126
N Engl J Med. 2016 Aug 11;375(6):523-33
pubmed: 27509101
Am J Obstet Gynecol. 2022 May;226(5):683-699
pubmed: 34437863
Reprod Biomed Online. 2017 Apr;34(4):422-428
pubmed: 28162937
Fertil Steril. 2015 May;103(5):1190-3
pubmed: 25747130
Hum Reprod. 2010 Aug;25(8):2092-100
pubmed: 20539042
Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Oct;14(5):815-26
pubmed: 11023802
Fertil Steril. 2008 Jan;89(1):20-6
pubmed: 17224151
N Engl J Med. 2018 Jan 11;378(2):137-147
pubmed: 29320655
Cochrane Database Syst Rev. 2017 Jul 05;7:CD003414
pubmed: 28675921
Curr Opin Obstet Gynecol. 1999 Jun;11(3):307-11
pubmed: 10369209
Hum Reprod. 2011 Oct;26(10):2593-7
pubmed: 21828116
Hypertension. 2019 Mar;73(3):680-690
pubmed: 30636549
Hum Reprod. 2012 May;27(5):1343-50
pubmed: 22362926
Hum Reprod. 2014 Aug;29(8):1698-705
pubmed: 24939956
Hum Reprod. 2017 Nov 1;32(11):2234-2242
pubmed: 29025055
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Hum Fertil (Camb). 2023 Jan 3;:1-8
pubmed: 36594497
Fertil Steril. 2019 Jun;111(6):1177-1185.e3
pubmed: 31029432
Fertil Steril. 2014 Jan;101(1):128-33
pubmed: 24268706
Front Endocrinol (Lausanne). 2020 Apr 30;11:255
pubmed: 32425886
Int J Reprod Biomed. 2018 Jan;16(1):9-18
pubmed: 29675483
Hum Reprod. 2015 Jul;30(7):1724-31
pubmed: 25924655
Fertil Steril. 1996 Dec;66(6):873-84
pubmed: 8941049
Hum Reprod. 2020 Jan 1;35(1):167-174
pubmed: 31953546
J Assist Reprod Genet. 2001 Apr;18(4):185-90
pubmed: 11432108
Hum Reprod. 2017 Sep 1;32(9):1786-1801
pubmed: 29117321
Fertil Steril. 2016 Apr;105(4):861-6
pubmed: 26940791
Fertil Steril. 2016 Jan;105(1):93-9.e1
pubmed: 26453267
Hum Reprod. 1993 Sep;8(9):1506-11
pubmed: 8253943
Thromb Res. 2022 Jan;209:23-32
pubmed: 34847404
Hum Reprod. 2018 May 1;33(5):869-876
pubmed: 29546361
Fertil Steril. 2017 Jul;108(1):72-77
pubmed: 28579406
Hum Reprod Update. 2019 Jan 1;25(1):2-14
pubmed: 30388233
Nature. 1983 Oct 20-26;305(5936):707-9
pubmed: 6633637

Auteurs

Annalisa Racca (A)

Reproductive Medicine Service, Dexeus University Hospital, Barcelona, Spain. annalisaracca@icloud.com.

Samuel Santos-Ribeiro (S)

IVI-RMA Lisbon, Lisbon, Portugal.
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.

Panagiotis Drakopoulos (P)

Centre for Reproductive Medicine, Brussels IVF, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Joran De Coppel (J)

Centre for Reproductive Medicine, Brussels IVF, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Lisbet Van Landuyt (L)

Centre for Reproductive Medicine, Brussels IVF, Universitair Ziekenhuis Brussel, Brussels, Belgium.

Herman Tournaye (H)

Centre for Reproductive Medicine, Brussels IVF, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Department of Obstetrics, Gynecology, Perinatology and Reproduction, Institute of Professional Education, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.

Christophe Blockeel (C)

Centre for Reproductive Medicine, Brussels IVF, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Department of Obstetrics and Gynecology, University of Zagreb-School of Medicine, Šalata 3, Zagreb, Croatia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH